What Arachitol-6L Treats: Main Uses and Benefits

Arachitol-6L, a high-dose form of cholecalciferol (Vitamin D3), is used to provide additional symptomatic support for Vitamin D deficiency and its related symptomatic manifestations. The medicine is commonly used when short-term symptomatic assistance is needed and helps ease the overall symptom load.

Therapeutic areas addressed include symptoms associated with osteomalacia, osteoporosis, and specific cases of related muscle pain or weakness. It is also applied in addressing conditions presenting with systemic imbalance.

---

Managing Bone Health and Deficiency Symptoms

This treatment is applied across domains where additional symptomatic support is needed, and is relevant for easing symptoms associated with conditions like osteomalacia and osteoporosis. It may assist with maintaining a sense of stability when symptoms are more noticeable and contributes to easing the overall symptom load.

Quick Fact: Supports ease of Physical Discomfort

---

Addressing Symptomatic Muscle Weakness

The medicine is relevant in contexts marked by increased discomfort or tension, helping address symptom clusters related to physical discomfort, such as muscle pain or weakness. It supports patients during difficult episodes by easing functional strain and may help patients cope more steadily with symptom fluctuations.

---

Supporting Immune Function and General Well-being

Arachitol-6L is used to address conditions presenting with systemic imbalance. It is considered relevant in situations requiring temporary assistance in systemic stabilization and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Arachitol-6L?

The eligibility for using high-dose Cholecalciferol (Arachitol-6L) is determined by strict regulatory criteria focused on preventing Vitamin D toxicity, primarily involving calcium metabolism and kidney function. Official regulatory documents define absolute prohibitions and conditional use.

Contraindications: Who Must Not Use

Use is strictly contraindicated (prohibited) for individuals with pre-existing conditions that signify dangerously high levels of calcium or Vitamin D. This includes Hypercalcaemia (high blood calcium), Hypercalciuria (high urinary calcium), and Hypervitaminosis D (excessive Vitamin D levels). The medicine is also contraindicated in patients with severe renal impairment and a history of kidney stones (Nephrolithiasis).

Population and Conditional Restrictions

Population Group	Regulatory Status
Children under 12	Not recommended due to high unit dose.
Pregnancy/Lactation	Use with caution (excessive doses must be avoided).
Non-severe Renal Impairment	Use with caution; requires frequent monitoring of calcium and phosphate levels.
Sarcoidosis	Use with caution due to increased sensitivity to Vitamin D.

Eligibility for use is generally established for adults with a verified Vitamin D deficiency requiring therapeutic intervention.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Cholecalciferol (Arachitol-6L) as defined by regulatory authorities.

---

Pharmacokinetic and Pharmacodynamic Interactions

The interaction profile is structured by substances that may alter the vitamin’s exposure or potentiate its effects on calcium levels.

Interaction Type	Interacting Substances (Examples)	Official Regulatory Description
Altered Metabolism	Phenytoin, Phenobarbital	Co-administration can reduce Cholecalciferol plasma concentration by accelerating its metabolic rate.
Altered Absorption	Mineral Oil, Bile Acid Sequestrants	These substances reduce the absorption of Cholecalciferol, requiring temporal separation of administration.
Additive Effects	Thiazide Diuretics, Calcium/Phosphate Supplements	May increase the risk of hypercalcemia or hyperphosphatemia due to compounded effects on mineral homeostasis.

---

Restrictions and Population Notes

Concurrent use with Cardiac Glycosides (e.g., Digoxin) is documented to increase the risk of hypercalcemia, which can potentiate the toxicity of the cardiac agent. The official profile notes increased interaction relevance in patients with renal impairment when co-administered with phosphate-binding agents, due to heightened risk of disturbed mineral balance. Glucocorticoids are documented to potentially reduce the overall effect of Vitamin D. Restriction on concurrent use with other high-dose Vitamin D analogs is generally advised.

Arachitol-6L contains the prohormone cholecalciferol ( Vitamin D3), which is biologically inert until sequential hydroxylation occurs in the liver and then the kidneys. This process generates the active metabolite, calcitriol (1,25- dihydroxycholecalciferol). Calcitriol functions as a key steroid hormone by binding to the nuclear Vitamin D Receptor ( VDR), a transcription factor present in target cells.

Binding of calcitriol to the VDR initiates gene transcription modulation, primarily in the small intestine. This cascade upregulates proteins required for the efficient absorption of dietary calcium and phosphate into the circulation. Simultaneously, calcitriol acts on bone tissue to modulate osteoblast and osteoclast activity, and on the kidneys to promote the reabsorption of calcium and phosphate. The integrated action of calcitriol across these organ systems governs systemic mineral balance and homeostasis.

How to Use Arachitol-6L: Official Administration Guidelines

Arachitol-6L, a high-dose preparation of Cholecalciferol (Vitamin D3), is used according to specific high-level patterns intended for the rapid correction of severe deficiency. The usage instructions primarily structure the treatment as a short-term, intensive repletion phase.

Administration Protocol

The central principle involves the use of a single unit dose of 600,000 International Units (IU), which defines an intermittent schedule, not a daily regimen. The dose is determined by the required correction of Vitamin D status, as confirmed by laboratory testing. The two approved methods of delivery are the Intramuscular (IM) injection and the high-concentration oral solution.

Procedural Conditions and Timing

Administration Aspect	Official Instruction Principle
Route of Delivery	Intramuscular injection or oral solution/capsule.
Dosing Frequency	Typically administered as a single bolus dose on an intermittent basis (e.g., once or periodically).
Oral Intake Timing	Oral forms must be taken with the main meal of the day to facilitate the proper absorption of this fat-soluble compound.
Supervision	Due to the high potency and the administration route, the dose is given under the direct supervision of a qualified healthcare professional.
Follow-Up Protocol	The high-dose correction phase is designed to be followed by a transition to a lower daily dose for long-term maintenance of Vitamin D levels.

If the high-dose oral medicine is part of a periodic regimen and a dose is missed, it should generally be skipped if it is almost time for the next scheduled dose; a double dose is not to be taken to compensate.

Research evidence / Overview of studies for Arachitol-6L

This section provides an overview of the research that has explored Arachitol-6L. It describes the types of studies conducted for specific conditions, how symptoms were measured in research settings, and what remains unknown about the product based on the current evidence landscape. Findings presented here describe group patterns observed in studies and should not be used for individual predictions or clinical decision-making.

---

Evidence for use in Depression

Research examined Arachitol-6L in adult populations with Major Depressive Disorder, focusing primarily on short-term changes. These were mainly randomized controlled trials (RCTs), which are studies that compare a product against a control or placebo over a short period. The findings describe patterns observed in the studies related to changes in depression rating scale scores, with reported score measurements sometimes showing patterns of both increase and decrease across different trials. Certainty remains low, as follow-up durations were limited, meaning long-term effects are not fully established.

---

Evidence for use in Anxiety

Arachitol-6L was evaluated in research exploring conditions characterized by fluctuating or episodic manifestations of anxiety. Studies explored short-term symptom changes, primarily using RCTs, where outcomes related to systemic or functional imbalance were assessed via disorder-specific anxiety rating scales. Data show patterns related to patient-reported outcomes describing perceived discomfort that were sometimes mixed across studies. The evidence is limited regarding the persistence of any measured change, and comparative evidence is lacking for certain specific anxiety sub-types.

---

Evidence for use in Pain

Research examined Arachitol-6L in conditions where symptoms may vary in intensity and are associated with acute or disruptive episodes. Studies monitored outcomes related to physical discomfort. Findings indicate patterns related to changes in patient-reported pain intensity scores from the start to the end of the research. Long-term outcomes are not fully established, and existing studies provide limited insight into how measured score changes correlate with sustained improvements in daily functioning or activity level.

---

What is still uncertain about Arachitol-6L

A number of research limitations exist in the current body of evidence. Sample sizes were modest across many studies, and follow-up durations were limited. Data for certain groups, such as older adults, children, or those with co-existing medical conditions, remain insufficient. Furthermore, the correlation between reported changes in symptom rating scale scores and real-world outcomes is not fully established by the existing research.

Key Studies & References

1. Effect of vitamin D supplementation on the incidence and prognosis of depression: An updated meta-analysis based on randomized controlled trials
2. Vitamin D in the Transition from Acute to Chronic Pain: A Systematic Review
3. Public Assessment Report Scientific discussion Cholecalciferol STADA Arzneimittel AG (Regulatory Documentation)

Common questions about Arachitol-6L (FAQ)

---

Q: Do I need a prescription to buy Arachitol-6L?

Official product information for Arachitol-6L indicates the dose is to be administered under the direct supervision of a qualified healthcare professional, which typically requires a prescription. This classification ensures the high-dose product is used appropriately for severe deficiency.

---

Q: Can Arachitol-6L cause any stomach upset or digestive issues?

According to official regulatory documents, adverse effects of Cholecalciferol may include symptoms related to the digestive system. These have been reported as nausea, vomiting, and constipation. Persistent or severe digestive upset is a symptom that should be discussed with a healthcare provider.

---

Q: Is Arachitol-6L safe for people with diabetes?

The official product documentation does not list diabetes as a specific contraindication (a reason to prohibit use). Research in government-funded databases has explored the effects of high-dose Vitamin D in patients with conditions like Type 2 diabetes. For patients with pre-existing conditions, such as diabetes, careful monitoring by a healthcare provider is generally recommended during treatment.

---

Q: Is Arachitol-6L suitable for vegetarians or vegans?

Cholecalciferol (Vitamin D3), the active ingredient, is often sourced from lanolin (sheep's wool fat). This makes the ingredient typically unsuitable for vegans. Specific ingredients in the formulation should be verified by consulting the product's official leaflet or a pharmacist, as the excipients may also affect suitability.

---

Q: Can Arachitol-6L affect sleep patterns?

Official safety profiles for high doses of Cholecalciferol include central nervous system effects associated with toxicity or overdose, such as fatigue and somnolence (drowsiness). If a person notices persistent changes in sleep patterns, they should consult a healthcare professional.

---

Q: Does Arachitol-6L have any known interactions with commonly used antacids?

Official information indicates that antacids containing aluminum may be a concern due to the risk of aluminum retention in the body. Additionally, antacids containing magnesium may increase the risk of hypermagnesemia in certain patients. Consult the official product information for a full list of known interactions.

---

Q: Are there any known allergic reactions associated with Arachitol-6L?

Regulatory documents report that hypersensitivity reactions are possible adverse reactions. These reactions may manifest as common skin issues like rash and urticaria (hives), or more severe swelling known as angio-oedema.

---

Q: Does Arachitol-6L need to be stored in the refrigerator?

Official storage guidelines specify that the medicine must be stored at a temperature below 25 C and protected from light. The product is generally not required to be refrigerated, provided the storage temperature remains below 25 C, and it must not be frozen.

---

Q: What is the connection between Arachitol-6L and immunity?

Official and scientific literature acknowledges that the active form of Vitamin D functions beyond bone health. It is recognized to play a supportive role in modulating immune function. This systemic activity is crucial for its overall therapeutic rationale.

---

Q: How long does a course of Arachitol-6L treatment usually last?

The high-dose treatment is generally prescribed as an intensive, short-term repletion phase for correcting a severe deficiency. This phase is typically followed by a long-term, lower-dose maintenance regimen. The exact duration of treatment is determined by a healthcare provider.

---

Q: Can Arachitol-6L be taken on an empty stomach?

Oral formulations of Vitamin D are fat-soluble, and official instructions advise they must be taken with the main meal of the day to facilitate proper absorption. Taking the medication with food containing fat helps ensure the body can utilize the high dose effectively.

---

Q: What clinical trials have been conducted on Arachitol-6L?

The regulatory approval of Arachitol-6L is based on data submitted from clinical trials that studied its efficacy and safety. The official product documentation (Summary of Product Characteristics) provides a summary of the findings from the studies submitted for regulatory approval.

---

How to Store and Dispose of Arachitol-6L

Official regulatory requirements establish specific conditions to ensure the stability and safety of Arachitol-6L (cholecalciferol) injection. The product must be stored at a temperature below 25 C and should not be frozen.

Storage and Handling

The medicine requires protection from environmental factors; it must be kept in a cool, dry place and protected from direct sunlight. The labeled instructions also mandate that the product be kept out of the sight and reach of children.

Disposal of Unused Medicine

Any unused portion of the medicine must be discarded. Disposal of the unused medicinal product or waste material must be carried out in accordance with local regulatory requirements.